explore -WSS

explore

author：hotspot 2025-10-01 01:50:39 - browse：9

At some point this summer, the drugmaker Novo Nordisk will release results from a closely watched study that, if successful, could further uncork demand for new obesity medications, streamline insurance coverage for the therapies, and demonstrate long-lasting health benefits.

The Select trial, as the study is called, is the first large, randomized trial to test whether long-term treatment with a weight loss drug can meaningfully improve patients’ cardiovascular health. Novo is testing Wegovy, a weekly injection also sold under the brand name Ozempic for type 2 diabetes, against placebo in the five-year study.

The implications are massive, and not just for Novo. Wegovy is part of a class of medicines that target a hormone called GLP-1, which curbs patients’ appetites. Those drugs have demonstrated an ability to help people lose dramatic amounts of weight in clinical trials, but payers, including Medicare, have been slow to reimburse for them without definitive data on their long-term health benefits.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： George Santos makes 1st court appearance after pleading not guilty to 13 counts
Next article： In Spain, a hospital brews its own CAR

WSS

NYC plans to house migrants on an island in the East River

Advocates call out 'SNL' over stereotypes, errors in sickle cell skit

Three trends to watch in biotech in 2024

Illinois to ban advertising for guns allegedly marketed to kids and militants

Why health records don't always know when patients are dead

Humana’s Medicare Advantage lawsuit should be tossed, DOJ says

Wikipedia

explore

knowledge

Cancer drug shortages should be causing more outrage

Boeing's 1st astronaut flight bumped into next year, more repairs needed

What does generative AI mean for health care? We asked experts

Why health care costs have stayed mostly flat since 2010

The high cost of giving birth even with insurance

Medicare drug price negotiation hasn't dried up venture capital

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Prince Harry and Meghan to work on film adaptation of 'Meet Me at the Lake' novel

State Dept. review finds Biden bears some blame for Afghanistan failures

David Ricks of Eli Lilly: best biopharma CEO of 2023

entertainment

Drinking less cuts risk of oral cavity, esophageal cancer: Report

Virtual care provider acquires bankrupt Pear's prescription apps

Arizona Democrat to raise extreme heat with Biden 1 year out from Senate primary

Thousands of Marines and sailors deploy to Middle East to deter Iran from seizing ships

NYC plans to house migrants on an island in the East River

Christmas in the PICU brings some surprising joy

knowledge

Wikipedia

focus

focus